Alcon Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alcon Inc. (ALC) develops, manufactures and markets innovative eye care products worldwide, operating through two primary segments: Surgical, which provides a comprehensive portfolio of technologies and devices for cataract, vitreoretinal and refractive surgery including advanced technology intraocular lenses such as PanOptix and Vivity to treat cataracts, presbyopia and astigmatism, phacoemulsification systems like Centurion, femtosecond laser systems, advanced viscoelastics, surgical packs and disposable products; and Vision Care, which offers daily disposable, reusable and color-enhancing contact lenses under brands including Dailies Total1 and Air Optix, lens care solutions, and ocular health products for dry eye, allergies, redness relief and vitamins. Founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner, the company is incorporated in Fribourg, Switzerland, with global headquarters in Geneva and its main operational base in Fort Worth where it employs around 4,500 people; it spun off from Novartis in April 2019 as a standalone public entity and conducts operations in 60 countries while serving patients in over 140 countries with products sold in more than 180 nations, including subsidiaries such as Aerie Pharmaceuticals for glaucoma therapies and WaveLight for laser eye surgery systems. Recent strategic expansions include agreements in 2025 to acquire LENSAR Inc. for approximately $356 million to integrate the ALLY Robotic Cataract Laser Treatment System and enhance femtosecond laser-assisted cataract surgery capabilities, STAAR Surgical Company for around $1.5 billion to add EVO implantable collamer lenses for myopia and astigmatism correction as a complement to laser vision procedures, a majority interest in Aurion Biotech for advanced cell therapies targeting eye diseases, and LumiThera Inc. for its photobiomodulation device treating early and intermediate dry age-related macular degeneration, with all transactions slated to close in mid-to-late 2025.
Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Here's Why Alcon (ALC) is a Strong Value Stock
Algoma Central Corporation Reports Financial Results for the 2026 First Quarter
Alcon Inc. (ALC) Q1 2026 Earnings Call Transcript
Swiss eye care firm Alcon's quarterly revenue rises, driven by product launches
New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds
ALC vs. PEN: Which Stock Should Value Investors Buy Now?
Alcon Announces Results of 2026 Annual General Meeting
Alcon Inc (ALC) Stock Down 3.1% -- Now Undervalued? GF Score: 80/100
Are Medical Stocks Lagging Alcon (ALC) This Year?
Crown Castle (NYSE:CCI) Stock Unloaded Rep. Josh Gottheimer
Rep. Josh Gottheimer Sells Off Shares of ENN Energy Holdings Ltd. (OTCMKTS:XNGSY)
La-Z-Boy (NYSE:LZB) Stock Unloaded Rep. Josh Gottheimer
Rep. Josh Gottheimer Sells Infineon Technologies AG (OTCMKTS:IFNNY) Stock
HDFC Bank (NYSE:HDB) Shares Unloaded Rep. Josh Gottheimer
Phreesia (NYSE:PHR) Shares Unloaded Rep. Josh Gottheimer
First Watch Restaurant Group (NASDAQ:FWRG) Shares Unloaded Rep. Josh Gottheimer
Rep. Josh Gottheimer Sells CBIZ, Inc. (NYSE:CBZ) Shares
Rep. Josh Gottheimer Purchases Shares of Air Products and Chemicals, Inc. (NYSE:APD)